Skip to content
Riskpilot
← Back to search
Sign in
Get full access
ImmuneBiotech Medical Sweden AB
AB
Active
Org 5569392813
Scheeletorget 1, 223 63
Lund
Research and experimental development on natural sciences and engineering
· NACE 7210
Est. 2013
1-4 employees
Watchlist
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
ImmuneBiotech Medical Sweden AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
0M
1M
2M
3M
3M
1M
2020
2M
2021
2M
2022
3M
2023
3M
2024
EBITDA
SEK millions
0M
-1M
-2M
-3M
-3M
-3M
2020
-5M
2021
-6M
2022
-8M
2023
-8M
2024
Income statement
SEK thousands
Item
2020
2021
2022
2023
2024
Revenue
691
1 643
2 412
2 824
2 747
Staff expenses
—
—
—
—
—
EBITDA
−3 467
−5 458
−5 667
−7 683
−8 015
Depreciation & amort.
−158
−158
−130
−133
−53
EBIT
−3 625
−5 616
−5 797
−7 816
−8 068
Net financials
—
−12
16
360
303
Profit before tax
−3 625
−5 629
−5 780
−7 456
−7 765
Tax
−0
−0
−0
−0
−0
Net profit
−3 625
−5 629
−5 780
−7 456
−7 765
Balance sheet
SEK thousands
Item
2020
2021
2022
2023
2024
Total assets
15 730
7 534
22 259
14 865
7 437
Equity
12 687
7 058
21 487
14 031
6 265
Long-term debt
0
0
0
0
0
Short-term debt
3 043
476
772
834
1 171
Total debt
3 043
476
772
834
1 171
Financial ratios
5-year trend
EBITDA margin
-291.8%
This company
15.8%
Market median
-1947% vs market
2020
2024
Equity ratio
84.2%
This company
38.2%
Market median
+120% vs market
2020
2024
Return on equity
-123.9%
This company
18.4%
Market median
-773% vs market
2020
2024
Net profit margin
-282.7%
This company
8.1%
Market median
-3590% vs market
2020
2024
Asset turnover
0.37×
This company
1.12×
Market median
-67% vs market
2020
2024
Debt / equity
0.19×
This company
0.62×
Market median
+69% vs market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
More on ImmuneBiotech Medical Sweden AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
